Table 5 Action plan results: outcomes in treatment phase II (restaging and surgical treatment)
Total patients | Centre A | Centre B | Centre C | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
ACOR-1 (N = 120) | ACOR-2 (N = 120) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | ACOR-1 (N = 120) | ACOR-2 (N = 120) | p-value | ACOR-1 (N = 40) | ACOR-2 (N = 40) | p-value | |
Was the restaging report available? | ||||||||||||
Yes | 39 (32.5%) | 73 (61.3%) | < 0.001‡ | 0 (0%) | 16 (40%) | < 0.001‡ | 31 (77.5%) | 37 (94.9%) | 0.057 | 8 (20%) | 20 (50%) | 0.01† |
No | 81 (67.5%) | 46 (38.7%) | 40 (100%) | 24 (60%) | 9 (22.5%) | 2 (5.1%) | 32 (80%) | 20 (50%) | ||||
Did the patient undergo surgery? | ||||||||||||
Yes | 116 (96.7%) | 108 (90%) | 0.035* | 40 (100%) | 33 (82.5%) | 0.018* | 37 (92.5%) | 37 (92.5%) | > 0.99 | 39 (97.5%) | 38 (95%) | 0.22 |
No | 3 (2.5%) | 12 (10%) | 0 (0%) | 7 (17.5%) | 3 (7.5%) | 3 (7.5%) | 0 (0%) | 2 (5%) | ||||
NR | 1 (0.8%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2.5%) | 0 (0%) | ||||
Staging (in patients undergoing surgical treatment) | ||||||||||||
0 | 19 (16.4%) | 20 (18.5%) | 0.54 | 7 (17.5%) | 5 (15.2%) | 0.52 | 7 (18.9%) | 9 (24.3%) | 0.93 | 5 (12.8%) | 6 (15.8%) | 0.53 |
I | 4 (3.4%) | 3 (2.8%) | 2 (5%) | 1 (3%) | 1 (2.7%) | 1 (2.7%) | 1 (2.6%) | 1 (2.6%) | ||||
II | 62 (53.4%) | 47 (43.5%) | 20 (50%) | 12 (36.4%) | 18 (48.6%) | 19 (51.4%) | 24 (61.5%) | 16 (42.1%) | ||||
III | 25 (21.6%) | 28 (25.9%) | 10 (25%) | 12 (36.4%) | 9 (24.3%) | 6 (16.2%) | 6 (15.4%) | 10 (26.3%) | ||||
IV | 6 (5.2%) | 10 (9.3%) | 1 (2.5%) | 3 (9.1%) | 2 (5.4%) | 2 (5.4%) | 3 (7.7%) | 5 (13.2%) | ||||
ypCRM (in patients undergoing surgical treatment) | ||||||||||||
Positive | 5 (4.3%) | 16 (14.8%) | < 0.001‡ | 1 (2.5%) | 4 (12.1%) | < 0.001‡ | 3 (8.1%) | 3 (8.1%) | 0.037* | 1 (2.6%) | 9 (23.7%) | 0.006† |
Negative | 71 (61.2%) | 86 (79.6%) | 15 (37.5%) | 26 (78.8%) | 28 (75.7%) | 34 (91.9%) | 28 (71.8%) | 26 (68.4%) | ||||
NR | 40 (34.5%) | 6 (5.6%) | 24 (60%) | 3 (9.1%) | 6 (16.2%) | 0 (0%) | 10 (25.6%) | 3 (7.9%) | ||||